Treatment response biomarkers are urgently needed for castration-resistant prostate cancer (CRPC). Baseline and post-treatment circulating tumor cell (CTC) counts...
CytoSorbents Corp announced the presentation of the final key results from the U.S. multicenter CytoSorb Therapy in COVID-19 (CTC) Registry at the 35th Annual Congress of the European Society of Intensive Care Medicine (ESICM) in Paris
Computerized tomographic colonography (CTC), also known as virtual colonoscopy, is comparable to standard colonoscopy in its ability to accurately detect...
Dermata Therapeutics, Inc. a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announces agreement with the FDA on the DMT 310 Phase III clinical protocols for the treatment of acne.
Dermata Therapeutics, Inc. announced that it has received a response from the FDA to the Company's Type C Chemistry, Manufacturing, and Controls ("CMC") meeting request
Nektar Therapeutics has presented biomarker data from a sub-study of the Phase III BEACON study of NKTR 102 (etirinotecan pegol)...
This is an official guideline of the European Society of Gastrointestinal Endoscopy (ESGE) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR). It addresses the clinical indications for the use of...
A multicentre prospective, randomised, phase II interventional study in mCRPC patients previously treated with 1?2 lines of chemotherapy and at least 12 weeks of abiraterone with a safety run?in and single stage phase II expansion cohort.
We proposed folate receptor-based assay to count circulating tumor cells (CTCs) to predict and dynamically monitor the therapeutic response to first-line EGFR-TKIs in patients with EGFR-mutated NSCLC.
Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis (see section 5.1).